Profile data is unavailable for this security.
About the company
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.
- Revenue in USD (TTM)85.00k
- Net income in USD-37.74m
- Incorporated2015
- Employees11.00
- LocationINmune Bio Inc225 Ne Mizner Blvd, Suite 640BOCA RATON 33432United StatesUSA
- Phone+1 (858) 964-3720
- Websitehttp://www.inmunebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verastem Inc | 10.00m | -89.49m | 109.06m | 73.00 | -- | 3.86 | -- | 10.91 | -3.34 | -3.34 | 0.3726 | 1.49 | 0.0672 | -- | 2.00 | 136,986.30 | -60.16 | -62.70 | -72.65 | -75.18 | -- | -- | -894.91 | -406.17 | -- | -- | 0.5052 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Annovis Bio Inc | 0.00 | -43.02m | 109.13m | 6.00 | -- | -- | -- | -- | -4.42 | -4.42 | 0.00 | -0.1494 | 0.00 | -- | -- | 0.00 | -308.78 | -106.31 | -395.89 | -124.71 | -- | -- | -- | -- | -- | -51.53 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -60.34m | 110.20m | 54.00 | -- | 1.68 | -- | -- | -2.00 | -2.00 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -67.81 | -80.06 | -80.19 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 110.30m | 9.00 | -- | 19.92 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 110.52m | -- | 6.41 | 0.2236 | 57.16 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Checkpoint Therapeutics Inc | 78.00k | -42.47m | 110.74m | 23.00 | -- | -- | -- | 1,419.79 | -1.50 | -1.50 | 0.0027 | -0.372 | 0.0111 | -- | 2.17 | 3,391.30 | -606.33 | -142.43 | -- | -342.79 | -- | -- | -54,444.87 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -12.36m | 111.02m | 4.00 | -- | 5.09 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -171.44m | 112.72m | 74.00 | -- | 0.7046 | -- | -- | -3.64 | -3.64 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -74.45 | -34.34 | -84.76 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0734 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| PDS Biotechnology Corp | 0.00 | -40.68m | 113.04m | 25.00 | -- | 3.65 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -19.47m | 113.92m | 10.00 | -- | -- | -- | -- | -0.939 | -0.939 | 0.00 | -0.073 | 0.00 | -- | -- | 0.00 | -171.13 | -- | -333.35 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
| Cardiff Oncology Inc | 665.00k | -40.88m | 114.51m | 31.00 | -- | 2.14 | -- | 172.20 | -0.9142 | -0.9142 | 0.0149 | 1.15 | 0.0081 | -- | 2.17 | 21,451.61 | -49.98 | -31.24 | -57.60 | -33.56 | -- | -- | -6,143.91 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| INmune Bio Inc | 85.00k | -37.74m | 115.08m | 11.00 | -- | 2.76 | -- | 1,353.82 | -2.06 | -2.06 | 0.0046 | 1.88 | 0.0014 | -- | 0.0311 | 7,727.27 | -61.78 | -37.82 | -80.24 | -41.86 | -- | -- | -44,402.35 | -14,901.03 | -- | -23.01 | 0.1184 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Assembly Biosciences Inc | 21.48m | -45.61m | 115.30m | 65.00 | -- | 3.32 | -- | 5.37 | -9.32 | -9.32 | 4.28 | 5.47 | 0.2362 | -- | 125.62 | 330,476.90 | -50.15 | -39.69 | -69.22 | -44.03 | -- | -- | -212.33 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| X4 Pharmaceuticals Inc | 563.00k | 17.63m | 118.49m | 93.00 | 8.21 | 1.25 | 6.56 | 210.46 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Adicet Bio Inc | 0.00 | -137.29m | 120.31m | 143.00 | -- | 0.5117 | -- | -- | -2.53 | -2.53 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -50.25 | -37.03 | -53.87 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Coherus Biosciences Inc | 308.13m | -29.34m | 120.97m | 246.00 | -- | -- | -- | 0.3926 | -0.4014 | -0.4014 | 2.74 | -0.7301 | 0.5385 | 2.86 | 1.95 | 1,006,974.00 | -5.13 | -21.43 | -11.46 | -29.32 | 41.51 | 79.01 | -9.52 | -36.56 | 1.07 | -4.02 | 1.47 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
Data as of Sep 19 2024. Currency figures normalised to INmune Bio Inc's reporting currency: US Dollar USD
18.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 748.73k | 3.79% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 604.03k | 3.05% |
| Heights Capital Management, Inc.as of 30 Jun 2024 | 596.37k | 3.02% |
| PRAETORIAN PR LLCas of 30 Jun 2024 | 485.00k | 2.45% |
| Geode Capital Management LLCas of 30 Jun 2024 | 323.20k | 1.63% |
| Raymond James Financial Services Advisors, Inc.as of 30 Jun 2024 | 227.53k | 1.15% |
| Rhenman & Partners Asset Management ABas of 30 Jun 2024 | 178.28k | 0.90% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 167.59k | 0.85% |
| MAI Capital Management LLCas of 30 Jun 2024 | 160.58k | 0.81% |
| Marshall Wace LLPas of 30 Jun 2024 | 115.92k | 0.59% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
